TNF, apoptosis and autoimmunity: A common thread?

Blood Cells, Molecules and Diseases

Volumn 24, Issue 2, 1998, Pages 216-230

  Beutler, Bruce ^a   Bazzoni, Flavia ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Autoimmunity; Cytokine; Fas ligand; Receptor; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CROHN DISEASE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 0032104725     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1998.0187     Document Type: Article

References (133)

1. 1. Wilson AG, de Vries N, Pociot F, Di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the human tumor necrosis factor -α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557-560, 1993.
2. 2. Whichelow CE, Hitman GA, Raafat I, Bottazzo GF, Sachs JA. The effect of TNF-β gene polymorphism on TNF-α and β secretion levels in patients with insulin-dependent diabetes mellitus and healthy controls. Eur J Immunogenet 23:425-435, 1996.
3. 3. Stokkers PCF, Camoglio L, Van Deventer SJH. Tumor necrosis factor (TNF) in inflammatory bowel disease: Gene polymorphisms, animal models, and potential for anti-TNF therapy. J Inflamm 47:97-103, 1996.
4. 4. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF α gene promoter. Scand J Immunol 42:501-504, 1995.
5. 5. Peruccio D, D'Alfonso S, Borelli I, et al. Distribution of tumor necrosis factor alleles (NcoI RFLP) and their relationship to HLA haplotypes in an Italian population. Hum Hered 43:103-110, 1993.
6. 6. Medcraft J, Hitman GA, Sachs JA, Whichelow CE, Raafat I, Moore RH. Autoimmune renal disease and tumour necrosis factor β gene polymorphism. Clin Nephrol 340:63-68, 1993.
7. 7. McManus R, Moloney M, Borton M, et al. Association of celiac disease with microsatellite polymorphisms close to the tumor necrosis factor genes. Hum Immunol 45:24-31, 1996.
8. 8. He B, Navikas V, Lundahl J, Söderström M, Hillert J. Tumor necrosis factor α-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 63:143-147, 1995.
9. 9. Fugger L, Morling N, Sandberg-Wollheim M, Ryder LP, Svejgaard A. Tumor necrosis factor alpha gene polymorphism in multiple sclerosis and optic neuritis. J Neuroimmunol 27:85-88, 1990.
10. 10. Duff GW. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol 23(Suppl. 100):9-19, 1994.
11. 11. Dawkins RL, Leaver A, Cameron PU, Martin E, Kay PH, Christiansen FT. Some disease-associated ancestral haplotypes carry a polymorphism of TNF. Hum Immunol 26:91-97, 1989.
12. 12. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 12:127-33, 1995.
13. 13. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, McKillop JH. Tumour necrosis factor-alpha (TNF-α) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 104:154-159, 1996.
14. 14. Brinkman BMN, Giphart MJ, Verhoef A, et al. Tumor necrosis factor α-308 gene variants in relation to major histocompatibility complex alleles and Felty's syndrome. Hum Immunol 41:259-266, 1994.
15. 15. Bouma G, Crusius JBA, Pool MO, et al. Secretion of tumour necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43:456-463, 1996.
16. 16. Badenhoop K, Schwarz G, Trowsdale J, et al. TNF-alpha gene polymorphisms in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32:445-448, 1989.
17. 17. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127, 1994.
18. 18. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110, 1994.
19. 19. Elliott MJ, Maini RN. New directions for biological therapy in rheumatoid arthritis. Int Arch Allergy Immunol 104:112-125, 1994.
20. 20. Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135, 1995.
21. 21. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670, 1975.
22. 22. Old LJ. Tumor necrosis factor. Clin Bull 6:118-120, 1976.
23. 23. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin: Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 259:686-691, 1984.
24. 24. Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem 260:2334-2344, 1985.
25. 25. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260:2345-2354, 1985.
26. 26. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J Exp Med 169:1747-1756, 1989.
27. 27. Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305, 1989.
28. 28. Falk MH, Trauth BC, Debatin KM, et al. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 79:3300-3306, 1992.
29. 29. Moller P, Henne C, Schmidt A, et al. Expression of APO-1, a cell surface molecule mediating apoptosis, during normal B cell ontogeny and in B cell tumors. Co-expression and coregulation of APO-1 and ICAM-1 (CD54) in germinal central cells. [German]. Verhandlungen Der Deutschen Gesellschaft Fur Pathologie 76:237-242, 1992.
30. 30. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 6:233-243, 1991.
31. 31. Dembic Z, Loetscher H, Gubler U, et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 2:231-237, 1990.
32. 32. Gray PW, Barrett K, Chantry D, Turner M, Feldmann M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci USA 87: 7380-7384, 1990.
33. 33. Kohno T, Brewer MT, Baker SL, et al. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 87:8331-8335, 1990.
34. 34. Loetscher H, Pan Y-CE, Lahm H-W, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61:351-359, 1990.
35. 35. Schall TJ, Lewis M, Koller KJ, et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61:361-370, 1990.
36. 36. Smith CA, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019-1023, 1990.
37. 37. Nagata S. Fas and Fas ligand: A death factor and its receptor. Adv Immunol 57:129-144, 1994.
38. 38. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976, 1994.
39. 39. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178, 1993.
40. 40. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 90:1756-1760, 1993.
41. 41. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992.
42. 42. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 90:334-341, 1992.
43. 43. Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, Murphy ED. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 133:227-233, 1984.
44. 44. Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159:1-20, 1984.
45. 45. Theofilopoulos AN, Balderas RS, Gozes Y, et al. Association of lpr gene with graft-vs-host disease-like syndrome. J Exp Med 162:1-18, 1985.
46. 46. Allen RD, Marshall JD, Roths JB, Sidman CL. Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J Exp Med 172:1367-1375, 1990.
47. 47. Douni E, Akassoglou K, Alexopoulou L, et al. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm 47:27-38, 1996.
48. 48. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNFα-deficient mice: A critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184:1397-411, 1996.
49. 49. Pfeffer K, Matsuyama T, Kündig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467, 1993.
50. 50. Rothe J, Lesslauer W, Lötscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802, 1993.
51. 51. Yang X-D, Tisch R, Singer SM, et al. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 180:995-1004, 1994.
52. 52. Yang X-D, McDevitt HO. Role of TNF-α in the development of autoimmunity and the pathogenesis of insulin-dependent diabetes mellitus in NOD mice. Circ Shock 43:198-201, 1994.
53. high/low T cell impalance, and suppression of type I diabetes mellitus result from TNF blockade in NOD→ NOD-scid adoptive T cell transfer. Diabetes In press, 1997.
54. 54. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF-β complex: Implications for TNF receptor activation. Cell 73:431-445, 1993.
55. 55. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 270:13303-13307, 1995.
56. 56. Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure 4:1251-1262, 1996.
57. 57. Van Lier RA, Borst J, Vroom TM, et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol 139:1589-1596, 1987.
58. 58. Borst J, Sluyser C, De Vries E, Klein H, Melief CJ, Van Lier RA. Alternative molecular form of human T cell-specific antigen CD27 expressed upon T cell activation. Eur J Immunol 19:357-364, 1989.
59. 59. Chapman BS, Kuntz ID. Modeled structure of the 75-kDa neurotrophin receptor. Protein Sci 4:1696-707, 1995.
60. 60. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497-14504, 1990.
61. 61. Bazzoni F, Alejos E, Beutler B. Chimeric tumor necrosis factor receptors with constitutive signaling activity. Proc Natl Acad Sci USA 92:5376-5380, 1995.
62. 62. Adam D, Kessler U, Krönke M. Cross-linking of the p55 tumor necrosis factor receptor cytoplasmic domain by a dimeric ligand induces nuclear factor-KB and mediates cell death. J Biol Chem 270:17482-17487, 1995, 1995.
63. 63. Moosmayer D, Wajant H, Gerlach E, Schmidt M, Brocks B, Pfizenmaier K. Characterization of different soluble TNF receptor (TNFR8O) derivatives: Positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. J Interferon Cytokine Res 16:471-477, 1996.
64. 64. Schreiber M, McFadden G. Mutational analysis of the ligand-binding domain of M-T2 protein, the tumor necrosis factor receptor homologue of myxoma virus. J Immunol 157:4486-4495, 1996.
65. 65. Schreiber M, Rajarathnam K, McFadden G. Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNF-a, but the dimer is a more potent TNF inhibitor. J Biol Chem 271:13333-13341, 1996.
66. 66. Hu F-Q, Smith CA, Pickup DJ. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 204:343-356, 1994.
67. 67. Smith CA, Davis T, Wignall JM, et al. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem Biophys Res Commun 176:335-342, 1991.
68. 68. Smith CA, Hu FQ, Smith TD, et al. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT-α. Virology 223:132-147, 1996.
69. 69. Bazzoni F, Beutler B. How do tumor necrosis factor receptors work. Circ Shock 45:221-238, 1995.
70. 70. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845-853, 1993.
71. 71. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFKB activation. J Biol Chem 272:2042-2045, 1997.
72. 72. Ansieau S, Scheffrahn I, Mosialos G, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 93:14053-14058, 1996.
73. 73. Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 12:1-9, 1996.
74. 74. Ishida T, Tojo T, Aoki T, et al. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 93:9437-9442, 1996.
75. 75. Ishida T, Mizushima S, Azuma S, et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 271:28745-28748, 1996.
76. 76. Nakano H, Oshima H, Chung W, et al. TRAF5, an activator of NF-KB and putative signal transducer for the lymphotoxin-β receptor. J Biol Chem 271: 14661-14664, 1996.
77. 77. Rothe M, Sarma V, Dixit VW, Goeddel DV TRAF2-mediated activation of NF-kappaB by TNF receptor 2 and CD40. Science 269:1424-1427, 1995.
78. 78. Rothe M, Xiong J, Shu HB, Williamson K, Goddard A, Goeddel DV. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 93:8241-8246, 1996.
79. 79. Sato T, Irie S, Reed JC. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett 358:113-118, 1995.
80. 80. Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci USA 93:13973-13978, 1996.
81. 81. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TBAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci USA 93:6721-6725, 1996.
82. 82. Tewari M, Dixit VM. Recent advances in tumor necrosis factor and CD40 signaling. Curr Opin Genet Dev 6:39-44, 1996.
83. 83. Tartaglia LA, Goeddel DV, Reynolds C, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 151:4637-4641, 1993.
84. 84. DeBenedette MA, Chu NR, Pollok KE, et al. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 181:985-992, 1995.
85. 85. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802, 1995.
86. 86. Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman SF, Morimoto C. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci USA 92:11249-11253, 1995.
87. 87. Heller RA, Song K, Fan N, Chang DJ. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70:47-56, 1992.
88. 88. Heller RA, Song K, Fan N. Cytotoxicity by tumor necrosis factor is mediated by both p55 and p70 receptors. Cell 73:216, 1993.
89. 89. Reid T, Louie P, Heller RA. Mechanisms of tumor necrosis factor cytotoxicity and the cytotoxic signals transduced by the p75-tumor necrosis factor receptor. Circ Shock 44:84-90, 1994.
90. 90. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505-512, 1995.
91. 91. Kimura M, Katagiri T, Kikuchi Y, et al. Role of bone marrow cells in autoantibody production and lympho-proliferation in the novel mutant strain of mice, CBA/KIJms-lprcg/lprcg. Eur J Immunol 21:63-69, 1991.
92. 92. Hsu HL, Shu HB, Pan MG, Goeddel DV TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299-308, 1996.
93. 93. Stanger BZ, Leder P, Lee T-H, Kim E, Seed B. RIP: A novel protein containing a death domain that interacts with Fas/Apo-1 (CD95) in yeast and causes cell death. Cell 81:513-23, 1995.
94. 94. Duan H, Dixit VM. RAIDD is a new 'death' adaptor molecule. Nature 385:86-89, 1997.
95. 95. Chinnaiyan AM, O'Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274:990-992, 1996.
96. 96. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85:803-815, 1996.
97. 97. Muzio M, Chinnaiyan AM, Kischkel FC, et al. Flice, a Novel FADD-Homologous ICE/CED-3-like protease, is recruited to the CD95 (FAS/APO-1) death-inducing signaling complex. Cell 85:817-27, 1996.
98. 98. Vincenz C, Dixit VM. Fas-associated death domain protein interleukin-1β enverting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. J Biol Chem 272:6578-6583, 1997.
99. 99. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346-347, 1994.
100. 100. Fearnhead HO, Dinsdale D, Cohen GM. An interleukin-1β-converting enzyme-like protease is a common mediator of apoptosis in thymocytes. FEBS Lett 375:283-288, 1995.
101. 101. Tanaka Y, Yoshihara K, Tohno Y, Kojima K, Kameoka M, Kamiya T. Inhibition and down-regulation of poly(ADP-ribose) polymerase results in a marked resistance of HL-60 cells to various apoptosis-inducers. Cell Mol Biol 41:771-781, 1995.
102. 102. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801-809, 1995.
103. 103. Schlegel J, Peters I, Orrenius S, et al. CPP32 apopain is a key interleukin 1β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem 271:1841-1844, 1996.
104. 104. Kaye KM, Devergne O, Harada JN, et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappaB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 93:11085-11090, 1996.
105. 105. Lee SY, Kandala G, Liou ML, Liou HC, Choi Y CD30/TNF receptor-associated factor interaction: NF-kappaB activation and binding specificity. Proc Natl Acad Sci USA 93:9699-9703, 1996.
106. 106. Lee SY, Choi Y TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med 185:1275-1285, 1997.
107. 107. Shu HB, Halpin DR, Goeddel DV. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 6:751-763, 1997.
108. 108. Mackay F, Rothe J, Bluethmann H, Loetscher H, Lesslauer W. Differential responses of fibroblasts from wild-type and TNF-R55-deficient mice to mouse and human TNF-α activation. J Immunol 153:5274-5284, 1994.
109. 109. Rothe J, Mackay F, Bluethmann H, Zinkernagel R, Lesslauer W. Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro. Circ Shock 44:51-6, 1994.
110. 110. Belka C, Wiegmann K, Adam D, et al. Tumor necrosis factor (TNF)-α activates c-raf-1 kinase via the p55 TNF receptor engaging neutral sphingomyelinase. EMBO J 14:1156-1165, 1995.
111. 111. Kalb A, Bluethmann H, Moore MW, Lesslauer W Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics. J Biol Chem 271:28097-28104, 1996.
112. 112. Krajcsi P, Dimitrov T, Hermiston TW, et al. The adenovirus E3-14.7K protein and the E3-10.4K/ 14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J Virol 70:4904-4913, 1996.
113. 113. Sedger L, McFadden G. M-T2: A poxvirus TNF receptor homologue with dual activities. Immunol Cell Biol 74:538-45, 1996.
114. 114. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78-81, 1995.
115. 115. McFadden G, Graham K, Ellison K, et al. Interruption of cytokine networks by poxviruses: Lessons from myxoma virus. J Leukocyte Biol 57:731-8, 1995.
116. 116. Miura M, Friedlander RM, Yuan JY. Tumor necrosis factor-induced apoptosis is mediated by a CrmA-sensitive cell death pathway. Proc Natl Acad Sci USA 92:8318-8322, 1995.
117. 117. Tufariello J, Cho S, Horwitz MS. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J Virol 68:453-462, 1994.
118. 118. Tufariello JM, Cho S, Horwitz MS. Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice. Proc Natl Acad Sci USA 91:10987-10991, 1994.
119. 119. Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WSM. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53:341-346, 1988.
120. 120. Wu JG, Wilson J, He J, Xiang LB, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lympho-proliferative disease. J Clin Invest 98:1107-1113, 1996.
121. 121. Bazzoni F, Beutler B. Comparative expression of TNF-α alleles from normal and autoimmune-prone MHC haplotypes. J Inflammation 45:106-114, 1995.
122. 122. Wollheim FA, Heinegard D, Palladino M, Saxne T, Talal N. Tumour necrosis factor alpha in synovial fluid. Difference between rheumatoid arthritis and reactive arthritis. Arthritis Rheumatol 30:S129, 1987.
123. 123. Beckham JC, Caldwell DS, Peterson BL, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 12:353-361, 1992.
124. 124. Brennan FM, Maini RN, Feldmann M. TNF alpha - a pivotal role in rheumatoid arthritis?. [Review]. Br J Rheumatol 31:293-298, 1992.
125. 125. Feldmann M, Brennan FM, Williams RO, et al. Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. [Review]. Prog Growth Factor Res 4:247-255, 1992.
126. 126. Giovine FD, Manson J, Nuki G, Duff G. Tumor necrosis factor (TNF) activity in synovial exudate fluids from patients with arthritic diseases. Lymphokine Res 6:1455, 1987.
127. 127. Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 22:1907-1912, 1992.
128. 128. Heilig B, Wermann M, Gallati H, et al. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Invest 70:22-27, 1992.
129. 129. Elliott MJ, Feldmann M, Maini RN. TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action. Int J Immunopharmacol 17:141-145, 1995.
130. 130. Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumour necrosis factor-alpha (TNF-α) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 101:207-12, 1995.
131. 131. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483-1489, 1991.
132. 132. Chesnut K, She JX, Cheng I, Muralidharan K, Wakeland EK. Characterizations of candidate genes for IDD susceptibility from the diabetes-prone NOD mouse strain. Mamm Genome 4:549-54, 1993.
133. 133. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1:219-229, 1994.